Along with the new emerging checkpoint inhibitors in lung cancer, it is expected that increasing the overall survival rate in lung cancer will involve detecting particular targetable gene mutations and PD-1/PD-L1 expression. This evidence concerns the gene CD274 and lung carcinoma.